Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Guidant Ventak AV II

This article was originally published in The Gray Sheet

Executive Summary

Guidant Ventak AV II: Firm's second-generation automatic implantable cardioverter defibrillator/dual-chamber pacing system for the treatment of arrhythmias will be available in the U.S. by mid-1998, Guidant says. The firm gained FDA sign-off on a premarket approval application supplement for the 73 cc, 136-gram system in mid-December. The device incorporates the company's Endotak lead and Triad three-electrode energy defibrillation system, and offers detection and diagnostic enhancements through its Quick Start and Auto Interrogate programming features, the company says. Guidant will discontinue availability of the Ventak AV once the AV II model reaches the market...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009368

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel